Thread by @NicholasAshton

I am delighted to share our latest blood biomarker work published in @alzassociation.

We investigated baseline & longitudinal #pTau, #NfL, #GFAP, #tTau, #Aβ to predict diagnosis & grey matter changes in individuals not predetermined by CSF/imaging.

alz-journals.onlinelibrary.wiley.com/doi/full/10.10…

1/n

2 - While all biomarkers were significantly changed in AD – only #pTau181 had a good accuracy in predicting AD dementia (AUC=0.91).

#pTau181 and #NfL were increased in MCI as compared to CU, and #pTau181 significantly increased in MCI converters versus non-converters

3 - Comparing baseline plasma measures with longitudinal structural MRI, we observed that #pTau181, and to a lesser extent #Aβ, was significantly associated with GM loss.

4 - Increasing concentrations of #pTau181 were significantly associated with GM loss overtime (A). However, longitudinal #Aβ was more strongly associated in CU (B) and #pTau181 confined to AD.

5 - Many congratulations to @JoelSimren on his first "first" authored paper. Also @AntoineLeuzy, @TommyKakari and @andrealessa on their important contributions!